Related Experiment Videos
Ideal anticoagulation for use with a left ventricular assist device
T Takahama1, F Kanai, K Onishi
1First Department of Surgery, Saitama Medical Center, Saitama Medical College, Japan.
Insights
For left ventricular assist devices (LVADs), combining a prostacyclin analogue with nafamostat mesilate (FUT-175) offers the most effective anticoagulation. This combination balances blood coagulation and fibrinolysis, unlike heparin or argatroban which cause bleeding.
Area of Science:
- Cardiovascular Science
- Hematology
- Biomedical Engineering
Background:
- Left ventricular assist devices (LVADs) are crucial for heart failure management.
- Effective anticoagulation is essential to prevent device thrombosis and bleeding complications.
- Current anticoagulation strategies require optimization for LVAD therapy.
Purpose of the Study:
- To evaluate the efficacy of various anticoagulants for LVAD support.
- To determine the optimal anticoagulant regimen for balancing coagulation and fibrinolysis.
- To identify strategies that minimize bleeding risks associated with LVADs.
Main Methods:
- Comparative study administering different anticoagulants: heparin, argatroban, protease inhibitor (nafamostat mesilate/FUT-175) alone, and a prostacyclin analogue (PG) with FUT-175.
- Assessment of blood coagulation and fibrinolysis activation markers.
- Evaluation of bleeding tendencies in relation to anticoagulant administration.
Main Results:
- LVAD support without anticoagulation markedly activates coagulation and fibrinolysis.
- Heparin and argatroban administration result in a significant bleeding tendency.
- Nafamostat mesilate (FUT-175) alone causes acceptable levels of coagulation activation.
- Combined administration of a prostacyclin analogue (PG) and FUT-175 effectively balances coagulation and fibrinolysis.
Conclusions:
- The combination of a prostacyclin analogue and nafamostat mesilate (FUT-175) is the most effective anticoagulation strategy for LVADs.
- This combined therapy provides optimal balance between preventing thrombosis and minimizing bleeding.
- Further research into optimized anticoagulation protocols for LVAD patients is warranted.
Abstract:
To establish ideal anticoagulation therapy for use with a left ventricular assist device, a study was done administering various anticoagulants: heparin, argatroban, a prostacyclin analogue combined with a protease inhibitor, or a protease inhibitor alone. Cardiac asisting by LVAD without any anticoagulants results in marked activation of blood coagulation or fibrinolysis. Administration of argatroban, as well as heparin, produces a bleeding tendency. Administration of a protease inhibitor (nafamostat mesilate, FUT-175) as a sole anticoagulant induces activation of the blood coagulation system to some extent, but it is within acceptable limits. Combined administration of a prostacyclin analogue (PG) and FUT-175 is most effective in maintaining balanced blood coagulation and fibrinolysis.